Blog Examines Respiratory Syncytial Virus Vaccine R&D

Bill & Melinda Gates Foundation’s “Impatient Optimists”: New Hope for Respiratory Syncytial Virus (RSV) Prevention
Niteen Wairagkar, senior program officer with the global health program’s pneumonia team at the Bill & Melinda Gates Foundation, discusses the need for and research into vaccines for respiratory syncytial virus (RSV), a leading cause of pneumonia in children, including one vaccine using a maternal immunization approach currently being tested in a phase 3 trial (12/10).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.